

UC Davis

UC Davis Previously Published Works

Title

A Genomically and Clinically Annotated Patient-Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer

Permalink

<https://escholarship.org/uc/item/1zw6561t>

Journal

Cancer Research, 82(22)

ISSN

0008-5472

Authors

Woo, Xing Yi
Srivastava, Anuj
Mack, Philip C
[et al.](#)

Publication Date

2022-11-15

DOI

10.1158/0008-5472.can-22-0948

Peer reviewed

A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer



Xing Yi Woo¹, Anuj Srivastava¹, Philip C. Mack², Joel H. Graber³, Brian J. Sanderson¹, Michael W. Lloyd³, Mandy Chen³, Sergii Domanskyi³, Regina Gandour-Edwards², Rebekah A. Tsai², James Keck⁴, Mingshan Cheng⁴, Margaret Bundy⁴, Emily L. Jocoy⁴, Jonathan W. Riess², William Holland², Stephen C. Grubb³, James G. Peterson³, Grace A. Stafford³, Carolyn Paisie¹, Steven B. Neuhauser³, R. Krishna Murthy Karuturi¹, Joshy George¹, Allen K. Simons³, Margaret Chavaree^{2,5}, Clifford G. Tepper², Neal Goodwin⁴, Susan D. Airhart³, Primo N. Lara Jr², Thomas H. Openshaw⁵, Edison T. Liu³, David R. Gandara², and Carol J. Bult³

ABSTRACT

Patient-derived xenograft (PDX) models are an effective preclinical *in vivo* platform for testing the efficacy of novel drugs and drug combinations for cancer therapeutics. Here we describe a repository of 79 genomically and clinically annotated lung cancer PDXs available from The Jackson Laboratory that have been extensively characterized for histopathologic features, mutational profiles, gene expression, and copy-number aberrations. Most of the PDXs are models of non-small cell lung cancer (NSCLC), including 37 lung adenocarcinoma (LUAD) and 33 lung squamous cell carcinoma (LUSC) models. Other lung cancer models in the repository include four small cell carcinomas, two large cell neuroendocrine carcinomas, two adenosquamous carcinomas, and one pleomorphic carcinoma. Models with both *de novo* and acquired resistance to targeted therapies with tyrosine kinase inhibitors are available in the collection. The genomic profiles of

the LUAD and LUSC PDX models are consistent with those observed in patient tumors from The Cancer Genome Atlas and previously characterized gene expression-based molecular subtypes. Clinically relevant mutations identified in the original patient tumors were confirmed in engrafted PDX tumors. Treatment studies performed in a subset of the models recapitulated the responses expected on the basis of the observed genomic profiles. These models therefore serve as a valuable preclinical platform for translational cancer research.

Significance: Patient-derived xenografts of lung cancer retain key features observed in the originating patient tumors and show expected responses to treatment with standard-of-care agents, providing experimentally tractable and reproducible models for preclinical investigations.

Introduction

Lung cancer is the leading cause of cancer deaths worldwide (1). Non-small cell lung cancer (NSCLC) differs from most other cancer

types both quantitatively and qualitatively for its high level of mutational burden and genomic complexity. Further, the two major histologic subtypes of NSCLC: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), have distinctive genomic alteration signatures, pathway disruption, and immune host response (2, 3). Transcriptional subtypes for both LUAD and LUSC have been reported that are associated with differences in patient prognosis, response to treatment, and survival (4, 5).

Genomic characterization of tumors has been instrumental in precision medicine strategies for NSCLC through the identification of “druggable” oncogene drivers, which, in turn, has expanded treatment options and a growing number of targeted therapy approaches (6). A prominent example of molecularly-guided therapy in NSCLC relates to the finding of activating mutations in the *EGFR* gene, resulting in constitutive, ligand-independent receptor activity and a high degree of sensitivity to *EGFR*-targeted tyrosine kinase inhibitors (TKI; refs. 7, 8). Targeted therapies have also been effective in treating other molecular subtypes, including *ALK-EML4* and *ROSI* fusions (9). Although advances in targeted therapies for NSCLC have transformed treatment options, not all patients respond to treatment and the development of acquired resistance is almost universal. Resistance mechanisms in some treatment settings for oncogene-driven NSCLC are well established, such as development of the T790M “gatekeeper” mutation after therapy with first- and second-generation *EGFR* TKIs (10). However, resistance mechanisms are much more complex in most other therapeutic settings, generally

¹The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.

²University of California Davis Comprehensive Cancer Center, Sacramento, California. ³The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine.

⁴The Jackson Laboratory, Sacramento, California. ⁵Eastern Maine Medical Center, Lafayette Family Cancer Center, Brewer, Maine.

Current affiliation for Neal Goodwin: Teknova, Hollister, California; current affiliation for Philip C. Mack, Icahn School of Medicine at Mount Sinai, New York, New York; current affiliation for Joel H. Graber, MDI Biological Laboratory, Bar Harbor, Maine; current affiliation for Thomas H. Openshaw, Cape Cod Hospital, Hyannis, Massachusetts; and current affiliation for Xing Yi Woo, Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore.

X.Y. Woo, A. Srivastava, P.C. Mack, and J.H. Graber contributed equally to this article.

Corresponding Author: Carol J. Bult, The Jackson Laboratory, 600 Main Street, RL13, Bar Harbor, ME 04609. Phone: 207-288-6324; E-mail: carol.bult@jax.org
Cancer Res 2022;82:4126–38

doi: 10.1158/0008-5472.CAN-22-0948

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

©2022 The Authors; Published by the American Association for Cancer Research

characterized as either secondary mutations or bypass mechanisms. Testing novel treatment strategies and new therapeutic agents to overcome acquired resistance remains a high priority for translational cancer research.

Human tumors or circulating tumor cells (CTC) engrafted into transplant-compliant recipient mouse hosts to produce patient-derived xenografts (PDX) and circulating tumor cell-derived explant models (CDX) retain critical biological properties of a patient's tumor, including tumor heterogeneity and genomic complexity (11, 12). PDXs have demonstrated utility as preclinical models for testing therapeutic strategies for many cancers, including lung cancer. Previous studies have demonstrated that lung cancer PDX models recapitulate faithfully many aspects of the original patient tumor for histology, karyotype, and genomics (13, 14), as well as expected sensitivity and resistance patterns to targeted therapies, including clinical responses observed in patients. These models have provided insights into therapies on the basis of other molecular markers (15, 16). Collections of PDX models have allowed further studies on understanding the contributing factors affecting engraftment rates, new treatment combinations for lung cancer models that developed resistance, and discovery of new biomarkers for lung cancer treatment (12, 17, 18).

In collaboration with the University of California Davis Comprehensive Cancer Center and Northern Light Eastern Maine Medical Center, we generated and characterized (19) a repository of 79 lung cancer PDX models to use as a platform for research for basic research on mechanisms of treatment response and to facilitate translational pre-clinical and co-clinical trial research. The PDX models were generated using the NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl}/SzJ (NSG) mouse strain as the host and includes models of high clinical relevance, including *EGFR*- and *KRAS*-mutated LUADs and PI3K-mutant LUSCs. Clinical demographic information, histology, IHC images, summarized genomic data, and treatment response data for these PDX models are freely available from The Jackson Laboratory (JAX) PDX web portal hosted by the Mouse Models of Human Cancer database (MMHCdb, <http://tumor.informatics.jax.org/mtbwi/pdxSearch.do>;

ref. 20) and from PDX Finder, a global catalog of thousands of PDX models (21).

Materials and Methods

Establishing xenografts

An overview of the PDX model generation process is shown in Fig. 1. All animal procedures were performed at The Jackson Laboratory Sacramento facility under IACUC protocol 12027. Tumor samples from biopsies, pleural effusions, or surgical resections were obtained from patients with lung cancer and implanted subcutaneously by trocar in the right flank of up to five, 6- to 8 week-old female NSG (JAX Stock 005557) mice without intervening *in vitro* culturing of the tumor cells. Written informed consent was obtained for patients by the donating institution to allow creation and unrestricted use of the models and associated data. Only tissues in excess of the materials needed for pathology evaluation (i.e., "surgical waste") were provided for PDX model generation. Most tumor samples were implanted within 24 hours of surgery and the maximum postsurgery time allowed for implantation was 48 hours. Solid tumors were divided into 3 to 5 mm³ fragments in RPMI medium before implantation. Pleural effusion samples were centrifuged, and the supernatant was removed with a pipet. Pellets were then resuspended in Dulbecco's PBS (DPBS), and 200 µL were implanted subcutaneously into the host mouse as a 1:1 bolus of pleural effusion cells in RPMI media and growth factor free Matrigel. Matrigel was not used for subsequent passages.

When an implanted tumor reached 2,000 mm³, it was harvested and subdivided into 3 to 5 mm³ fragments, which were implanted into five, 6- to 8-week-old female NSG mice for expansion to P1. For quality control assessment (see below), a 50 mm³ fragment was collected in 10% neutral-buffered formalin and a formalin-fixed, paraffin-embedded block was generated. The remaining fragments were cryopreserved in 10% DMSO. When P1 tumors reached ~2,000 mm³, they were harvested and subdivided into 3 to 5 mm³ fragments, which were subsequently embedded in FFPE for quality control, snap-frozen for genomics, placed into RNALater (Ambion) for RNA sequencing




Figure 1.

Schematic overview of the process for PDX model generation and characterization for the JAX PDX Resource.

(RNA-seq), and viably cryopreserved in a solution of 10% DMSO in DMEM with 1% penicillin–streptomycin.

To establish cohorts of tumor-bearing mice for drug treatment studies, 3 to 5 mm³ tumor fragments or 40 μ L of minced tumor were subcutaneously implanted in the right rear flank of NSG mice by trocar or a 14-gauge disposable needle. Low passage tumor fragments (P3–P6) were used to establish cohorts of tumor-bearing animals for dosing studies. Tumor volumes were monitored with ULTRA-Cal IV digital calipers (Fowler). Individual tumor-bearing mice were randomized into treatment cohorts of 8 to 12 mice each on an accrual (asynchronous growth) basis once individual tumors reached an initial volume of 70 to 300 mm³. For some studies, tumors were removed and divided, with half of the material preserved in neutral-buffered formalin and half flash-frozen.

PDX model quality control

The quality control procedures employed for PDX models included testing the patient tumor for lymphocytic choriomeningitis virus (LCMV) and bacterial contamination. Engrafted tumors at P0 and P1 were DNA fingerprinted using a short tandem repeat (STR) assay (22) and then compared with the profile of the patient sample to ensure correct tissue provenance. IHC for human CD45 antibodies (IR75161–2; Agilent Technologies) was performed on FFPE blocks of engrafted tumors to identify cases of lymphomagenesis, which have been reported previously in PDXs (23). IHC for human Ki67 (IR62661–2; Agilent Technologies) was used to ensure the propagated tumors were comprised of human cells. Hematoxylin and eosin sections of engrafted tumors were evaluated by a board-certified pathologist (RGE) to verify the concordance of the morphologic features of the engrafted tumor to the patient tumor. Engrafted tumors were assessed by sequencing or digital droplet PCR to determine if diagnostic/therapeutic molecular markers identified in patient samples were present in the engrafted tumors (Supplementary Table S1).

Genomic characterization of engrafted tumors

The DNA and RNA of engrafted tumors were characterized at the P0 and/or P1 passage (Fig. 1) using a targeted gene panel [JAX Cancer Treatment Profile (CTP)] sequencing (24), Affymetrix Human SNP array 6.0, and expression microarrays or RNA-seq. Detailed protocols for nucleic acid extraction, library preparation, and data analysis are described elsewhere (19). The JAX Clinical Knowledge Base (CKB) was used to annotate clinical relevance of variants and gene expression (25).

Analysis of genomic data from engrafted tumors

Mutation, copy number (CN) and gene expression analyses were performed as described in Woo and colleagues (19). Tumor mutation burden (TMB) was calculated using variants that met all quality criteria (coverage, strand bias, mapping quality, and read rank position) and were not present on a curated list of false-positive variants (loci prone to sequencing and analysis errors and/or associated with highly polymorphic genes: *MUC4*, *MUC5B*, *MUC16*, *MUC17*, and *HLA-A*). Only somatic mutations on the basis of germline filtering criteria that were predicted with high or moderate functional impact (i.e., nonsynonymous changes, frame shifts, stop losses/gains, and splice-site acceptor/donor changes) were retained. TMB was estimated by dividing the number of variants that met the quality criteria by the length (in Mb) of the CTP gene panel. High TMB was defined as 22 mutations/Mb (calculated on the basis of the TMB distribution of all PDX models analyzed as follows: third quartile + 1.5 \times interquartile range). The MSIsensor2 (26) algo-

rithm was used to determine microsatellite instability (MSI) status of engrafted tumors. Tumors with MSI percentage >20% were classified as MSI-High and those <20% as MSI-Stable.

To summarize the mutations prevalent in the PDX models, onco-plot (maftools v2.2.10; ref. 27) for both subtypes were created using all the somatic and clinically relevant point mutations and indels that occurred at a frequency >30%. For PDXs with more than one sequenced sample data from all samples were combined to derive a unique list of mutations per model. Gene mutation frequencies of LUAD and LUSC in The Cancer Genome Atlas (TCGA) PanCancer Atlas were obtained from cBioPortal (28) for comparison with the PDX data. Genes were classified as oncogenes or tumor suppressor genes (TSG) based on OncoKB annotations (download date: 2020/9/17; ref. 29).

CN data were visualized using GenVisR (30) on a per-sample basis and an overall gain and loss frequency basis within the subtypes. For frequency calculation, one sample was selected to represent each model, and $\log_2(\text{CN ratio}) = \pm 0.5$ was used as a cut-off to call CN gain and loss.

To summarize the expression data, the percentile rank z-score values from stranded RNA-seq, nonstranded RNA-seq, and microarray platforms were combined and a correlation heatmap was plotted using the Pretty Heatmaps package in R (<https://cran.r-project.org/web/packages/prettyheatmap/index.html>).

Gene expression-based subtypes of LUAD and LUSC PDXs

To determine if previously identified transcriptional subtypes for LUAD (TRU: terminal respiratory unit, PIF: proximal inflammatory, PPR: proximal proliferative) and LUSC (CLA: classical, PRI: primitive, BAS: basal, and SEC: secretory) were represented in our repository of lung cancer PDX models, we used nearest template prediction (NTP) implemented in the R package CMScaller. We selected genes from publicly available RNA-seq data to enrich for classification of the subtypes, following similar methods reported in Eide and colleagues (31). TCGA raw gene expression data (nonstranded RNA-Seq) were downloaded from the Broad GDAC Firehose repository for LUAD (7) and LUSC (32). Molecular subtype annotations for LUAD and LUSC samples from TCGA were downloaded using the TCGA_query_subtype function in the R package TCGAbiolinks (33). Gene expression data were harmonized between TCGA and PDX samples and filtered for lowly expressed genes (mean normalized expression ≤ 1). We estimated differential expression between subtypes in TCGA samples using the R package DESeq2 v. 1.28.1 (34). Genes were classified as differentially expressed for each subtype using a threshold of an FDR-adjusted *P* value of ≤ 0.01 and an absolute \log_2 fold-change value >1. All differentially expressed genes that showed discrimination between at least one subtype and the others (i.e., not commonly identified as differentially expressed among all subtypes) were included to generate custom templates for NTP. We also selected genes that showed a large range of expression values among LUAD and LUSC cell lines in the Cancer Cell Line Encyclopedia (35) and highly expressed in at least a subset of the cell lines. Finally, we selected genes to exclude from the training set by performing a differential expression analysis between matched patients with lung cancer (seven samples) and PDX samples (41 samples) obtained from the NCI patient-derived model repository (PDMR; NCI-Frederick, Frederick National Laboratory for Cancer Research, <https://pdmr.cancer.gov/>), using DESeq2. The genes with an absolute \log_2 fold change ≥ 1 were excluded from the model training set as they may be lost upon engraftment.

The final list of genes used to train the NTP classifiers included 3,525 genes for LUAD and 3,544 genes for LUSC. Raw expression data

from TCGA for these genes were used to generate templates for NTP. TCGA samples were split randomly into 80% training and 20% validation sets stratified by labeled subtype. Custom templates were then prepared for LUAD and LUSC training sets using subDEG and ntpMakeTemplates in the R package CMScaller. Subtype prediction performance was estimated using the validation sets with the function ntp in the CMScaller, specifying 1,000 permutations. Performance of subtype predictions from NTP was calculated using 20% of the labeled TCGA data held back for validation. For each subtype, the performance of the NTP classification was measured by precision, recall, and F1-score. The overall accuracy of the predictions was calculated as the unweighted average of the proportion of true positives to samples of each subtype. Finally, we used the custom templates to generate subtype predictions for the unlabeled PDX models with non-stranded RNA-seq data, and we considered high confidence subtype classifications with FDR-adjusted *P* values <0.05.

PDX treatment studies

Tumor-bearing mice at low passage (P3–P6) were assigned to cohorts (8–10 mice per treatment group) and treated with single and combination agent therapies depending on the lung cancer subtype and presence of targetable molecular markers. Vehicle-treated mice were used as controls. Treatment was initiated when tumors reached approximately 70 to 300 mm³. Tumors were monitored until the end of the dosing study (typically 28 days) or when the tumors reached 2,000 mm³. To monitor for toxicity effects from treatment, animal body weight was monitored three times weekly throughout the study, and percent body weight loss was calculated for each mouse. Animals with >20% body weight loss were euthanized and recorded as treatment-related deaths. Tumor volumes were calculated from digital caliper raw data by using the formula: Volume (mm³) = (*l* × *w*²)/2.

Treatment responses were calculated on the basis of the percentage of tumor volume change (Δ Vol) at the final study day (i.e., seven days after the last treatment) compared with the baseline tumor volume at Day 0 or Day 1. Responses were classified using a modified RECIST method adapted from Gao and colleagues (36). Classification method details are available from the PDX data portal via MMHCdb. Graphical summaries of treatment responses for individual models were generated using custom software (<https://github.com/TheJacksonLaboratory/PDX-SOC>) are also available from MMHCdb. Graphical summaries of treatment responses across all models were generated using the R package Xeva (version 1.6.0; ref. 37).

Western blots

Immunoblotting was performed on treated tumors using methods described previously (38).

Data availability

Information and data for the PDX models described in the article and its supplementary data are freely available from the Mouse Models of Human Cancer database (MMHCdb, <http://tumor.informatics.jax.org/mtbwi/pdxSearch.do>) and from PDX Finder (<https://www.pdxfinder.org/data/search>) using the model identifiers included in Supplementary Table S1.

Results

Enrollment and patient characteristics

The clinical and demographic data for the patients from whom the lung PDX models were generated are summarized in **Table 1**.

Table 1. Summary of clinical and demographic data for patients whose tumor material was used to generate the JAX collection of lung cancer PDX models.

Characteristics	Adenocarcinoma (LUAD)	Squamous cell carcinoma (LUSC)	All other lung cancers
<i>N</i> =	37	33	9
Age			
Median (range)	58 (42–79)	67 (50–85)	60 (50–78)
Sex			
Female/male	24/13	12/21	8/1
Race/ethnicity			
White/Not Hispanic	22	16	6
White/Not reported	5	11	1
White/Hispanic	1	0	0
Asian or Pacific Islander/Not Hispanic	5	1	0
American Indian or Alaskan Native/Not Hispanic	1	1	0
American Indian or Alaskan Native/Hispanic	0	1	0
Not Reported/Not Hispanic	1	1	0
Not Reported/Not reported	2	2	2
Tumor type			
Primary/relapse/metastatic	22/1/14	31/1/1	7/0/2
Stage			
I (A,B)	4	7	2
II (A,B)	5	9	0
III (A,B)	5	9	3
IV (A,B)	23	4	3
Not reported	0	4	1
Smoking status			
Smoker	7	6	3
Former	15	17	3
Never	6	0	0
Unknown	9	10	3
Treatment naïve?			
Y/N/unknown	19/16/2	30/2/1	5/3/1

The median age for patients was 63 (range 42–85). Slightly more female (*n* = 44) versus male patients (*n* = 35) are represented in the patient population from which the models were derived. Most patients (80%) reported their race as White. The self-reported smoking status of the patient cohort was as follows: former (44%), current (20%), and never (8%). Most of the patients (30 of 33) diagnosed with LUSC were treatment naïve at the time their tumor tissue was acquired to generate a PDX model. For LUAD, half of the patients (19 of 37) were treatment-naïve at the time of PDX model generation.

PDX models

A summary of the 79 lung PDX models described in this report is presented in Supplementary Table S1. The collection of models is comprised mostly of LUAD (37 models) and LUSC (33 models). The

collection includes two LUAD models developed from a primary and metastatic lesion from the same patient (TM00233 and TM01357). Models for other lung cancer types available from the repository include four small cell carcinomas, two large cell neuroendocrine carcinomas, two adenocarcinomas, and one pleomorphic carcinoma. Only the LUAD and LUSC models were used in the analyses described in this report. On average, 38% of implantations resulted in successful engraftment, similar to other reports on lung cancer PDXs (34%–39%; ref. 17).

Quality control

All patient tumor samples were negative for LCMV. All engrafted tumors demonstrated positive labeling for human Ki67 protein. Results of STR analysis for each model confirmed the engrafted tumor originated from the expected patient tumor. All models for which hematoxylin and eosin-stained slides were available for both patient and engrafted tumors data were determined to have moderate to high concordance following visual evaluation of the images by a board-certified pathologist (RGE).

Of 95 tumors engrafted, 13 (16%) were identified as lymphoid tumors based on positive staining for human CD45 antigen. These tumors likely arose from transplanted Epstein-Barr Virus (EBV)-infected human B cells (39). The corresponding PDX models were removed from the JAX repository, resulting in the final set of 79 models described here. A similar percentage of lymphomagenesis was reported in another PDX lung cancer model collection (40).

The Xenome (41) algorithm was used to determine human and mouse origins of sequence data generated from engrafted tumor samples. The average percentage of human sequences was 87% (53%–99%) and 79% (50%–89%) for the CTP assay and RNA-seq, respectively (Supplementary Fig. S1). The average percentage of mouse sequences identified by Xenome were ~12% (0.5%–47%), and the percentage of sequence reads that were classified as “both” or “ambiguous” were <0.2% and ~0.6% for both platforms, respectively. The “neither human nor mouse” category averaged 0.04% for CTP and 7.8% for RNA-seq. The observed differences in the percentages of mouse and human sequences are likely due to platform differences (sequence capture method for CTP compared with direct sequencing for RNA-seq). The difference between the platforms was significant for human reads (Welch two sample *t* test; *P* value = 2.19×10^{-8}) but not for reads classified as mouse.

Genomic characterization: somatic mutation

Genes on the JAX CTP panel that were mutated in at least 30% of the LUAD and LUSC PDX models are summarized in **Fig. 2A** and **B** (see Supplementary Table S2 for complete gene list). As has been observed previously in many human cancers, *TP53* is the most commonly mutated gene in both LUAD and LUSC (7, 32).

An evaluation of mutation frequencies between LUAD and LUSC in the JAX PDX repository revealed that mutation frequencies in some genes are characteristic of the NSCLC subtype (**Fig. 2C**). Because of the relatively small number of PDX models in this analysis, these trends cannot be considered definitive. However, several of the patterns in the JAX collection are also observed in the TCGA PanCancer Atlas from cBioPortal (**Fig. 2D**; ref. 28). Genes that are more frequently mutated in LUSC in both JAX PDX and TCGA datasets include *NFE2L2*, *TP53*, and *MUC4*. Genes that show higher mutation frequencies in LUAD in both datasets include *KRAS*, *EGFR*, *NOTCH4*, *HMCN1*, and *MUC17*. Other genes identified as being characteristic of LUAD and LUSC in one but not both data sets. For example, mutations in *AURKA* and *FER1L5* were characteristic of LUAD tumor in the JAX data set but not

TCGA; mutations in *TET2* were characteristic of LUAD in the JAX data but is reported as being more frequently mutated in LUSC in the TCGA data; *ALK* mutations were higher in LUSC tumor in the JAX data but occur more frequently in LUAD tumors in the TCGA data set. Several factors could explain these differences. First, the JAX PDX samples were sequenced at very high coverage (mean coverage = 941x) compared with the whole-exome sequencing of TCGA samples (~100x; ref. 42). Second, the types of samples used to generate the two resources differ. The tumor types used to generate the JAX resource were often selected by collaborating clinical oncologists based on known clinical (e.g., stage, prior treatment, metastasis, relapse) and/or genomic features. Finally, a greater proportion of late-stage tumors (stage II or later) are found in the JAX PDX models (LUAD: 89%, LUSC: 63%) compared with TCGA PanCancer Atlas (LUAD: 41%, LUSC: 51%; Supplementary Fig. S2).

For 22 of the LUAD PDX models, genomic testing data for the patient tumor was provided. All the engrafted tumors retained the clinically relevant mutations of the donor patient's tumor (Supplementary Table S1). For model TM01244, the expected *EGFR* T790M mutation was not observed in the sequence data from the CTP targeted gene panel, but the presence of the mutation was confirmed by droplet digital PCR (ddPCR). The failure of the targeted gene sequencing to identify the mutation in this case could be due to the random sampling of subclones from a heterogeneous patient tumor in the sample used to establish the PDX model (11, 43).

Although patients with LUSC have limited targeted treatment options compared with those diagnosed with LUAD, recent findings of recurrent genomic alterations that are characteristic of this histologic subtype, including activating alterations in *PIK3CA*, *KRAS*, and *MET*, provide future therapeutic avenues for research (44). Within the JAX PDX collection, clinically relevant alterations of these genes were found in 26 of the LUSC models (Supplementary Table S1).

Patient tumor genomics was tested before establishing the PDX model, in which the *KRAS* G12C mutation was also observed in the engrafted tumor (TM00231). Patient tumors of TM01243 and TM01448 were assayed on the same platforms, and two of four of the alterations can be detected in the PDXs.

Considering both LUAD and LUSC models, 97% (*n* = 68/70) of the engrafted tumors harbored clinically relevant alterations based on annotations from the JAX CKB database (25). As TMB and MSI are used as biomarkers for immunotherapy response (45–49), we observed trends similar to other lung cancer data sets, where lung tumors are rarely MSI-high, but do have high TMB scores (Supplementary Fig. S3; Supplementary Table S1). Within the JAX PDX collection, none of the lung cancer PDX models are MSI-high (MSI score > 20), whereas 10 of the models are classified as high tumor mutation burden (TMB score > 22). The MSI and TMB scores are similar across multiple samples and passages of the same model, indicating that these genomic features are maintained throughout passaging and expansion.

Genomic characterization: copy-number alteration

Recurrent gains and losses of chromosomal regions have been documented in NSCLC previously, including gains in *MYC*, *EGFR*, *CCND1* and losses in *LRP1B* and *CDKN2A* (7, 32). In LUSC, gains in 3q and losses in 3p and 5q occur more frequently than in LUAD (50). An overview of the gains and losses observed in engrafted tumors from LUAD and LUSC PDX models is provided in **Fig. 3A** and **B**, respectively. Gain and loss frequencies of individual genes are provided in Supplementary Table S3. The frequently amplified and deleted chromosomal regions are consistent with previous studies.




Figure 2. **A** and **B**, Oncoplot of the most frequently mutated genes in LUAD (**A**) and LUSC (**B**) PDX models. The oncoplot shows the PDX models in a horizontal orientation, annotated with smoking status, gender, treatment naïve status, stage of cancer, and tumor type. Genes with mutation frequency >30% are shown on the vertical axis. The barplot at the top has the frequency of mutations for each PDX model, whereas the right barplot has the frequency of mutations in each gene. Colors in the oncoplot columns indicate different mutation types (see legend for details). The bottom panel shows the classification of the SNPs into transitions and transversions. Model IDs in red originate from the same patient. **C**, Comparison of gene mutation frequency in LUAD and LUSC PDX models (frequency >30%). **D**, Comparison of gene mutation frequency in LUAD and LUSC TCGA samples (left, frequency >10%; right, frequency < 10%). Oncogene and TSG annotations from OncoKB.

Copy-number profiles of individual PDX samples for LUAD, LUSC, and other lung cancer subtypes are shown in Supplementary Figs. S4A–S4C, respectively. Amplifications reported for patient tumors were also observed in the corresponding PDX model. For example, *MET*, *EGFR*, and *MYC* amplifications reported in a patient tumor were recapitulated in the corresponding PDX model (TM00784). Different engrafted tumor samples derived from the same PDX model had high concordance in copy number (11).

Genomic characterization: transcriptional profiling

Unsupervised hierarchical clustering of gene expression data for engrafted tumors revealed that samples clustered primarily by the

platform (RNA-seq or microarray) and then by the diagnosis (**Fig. 4A**). Tumor samples derived from the same PDX model were highly correlated regardless of platform (Supplementary Fig. S5), indicating that the expression profile is retained during engraftment, expansion, and passaging.

Consistent with previous reports we observed a positive correlation between the copy number of amplified and deleted genes and gene expression level across 63 lung PDX tumor samples assayed for both copy number and expression profiles (Pearson correlation coefficient = 0.54; $P < 10^{-15}$) for a subset of frequently amplified and deleted genes in both LUAD and LUSC PDX models (Supplementary Fig. S6A; ref. 51). Supplementary Fig. S6B shows the concordance




Figure 3.

Frequency of copy-number gain and loss for LUAD (A) and LUSC (B) PDX models. CN gain, $\log_2(\text{CN}/\text{ploidy}) > 0.5$; CN loss, $\log_2(\text{CN}/\text{ploidy}) < -0.5$. One sample per model was used to calculate the frequency.

between gene expression and the copy number for these genes individually. We observed that most tumors with copy-number alterations in oncogenes exhibit both copy number and expression gains. Conversely, tumor samples with copy-number alterations in TSGs exhibit both copy number and expression losses. On the basis of these examples, it is evident that the amplification status elevates the gene expression levels of these frequently amplified oncogenes. Similarly, the deletion status decreases the gene expression levels of these frequently deleted TSGs.

The patient tumor associated with model TM01244 was noted as having elevated *MET* expression, but this property was only recapitulated as low-level overexpression (percentile rank z -score = 0.44–0.51) in the engrafted tumors. Given that the *EGFR* T790M mutation present in the patient tumor was detected in the PDX tumor only after ddPCR, it is plausible that the patient tumor fragment used to establish the model was not representative of the clonal population used for genomic testing of the patient or that the tumor cells that were positive for the markers were out competed by other cancer cells in the mouse host.

Transcriptional subtyping

We adapted a PDX molecular subtyping tool developed for colorectal cancer PDX models, CMScaller (31), to classify the expression subtypes for the LUAD and LUSC models (4, 5, 52). Using the training set from TCGA yielded 793 and 1,224 template genes to classify LUAD and LUSC subtypes, respectively (Supplementary Tables S7 and S8), resulting in high accuracies of 93% and 92% for the TCGA validation set (Supplementary Table S4). For the JAX PDX models, 31 of 36 LUAD samples and 24 of 24 LUSC samples were classified in expression subtype categories with high

confidence (FDR-adjusted P values < 0.05 ; Supplementary Tables S5 and S6). Among the LUAD samples, 32% were classified as PIF, 32% as PPR, and 35% as TRU. Among the LUSC samples, 38% were classified as BAS, 38% as CLA, 8% as PRI, and 17% as SEC. For models with multiple samples, all were predicted as the same subtype within each model, except for LUSC model TM01448 in which PT and P0 were classified as BAS and SEC, respectively. We hypothesize that spatial tumor heterogeneity in the tumor sample that was used to establish the PDX model is the source of these classification differences (53). The patient and P0 tumor samples of this model share the same clinically relevant mutations except for a *PTEN* nonsense mutation that was detected only in the PT sample.

To further confirm the reliability of the classifications, we compared the expression of the template genes between TCGA samples with known subtype labels and the predicted subtypes of the samples of the PDX models. We observed high correlation within the template genes of each respective LUAD or LUSC subtype (Fig. 4B). This confirms that the expression level of the template genes is replicated in the lung cancer PT/PDX samples. The subtypes were also enriched in other genomic alteration profiles (5, 7, 32, 52). Despite the limited number of samples, we observed higher proportion in some of the reported subtype-enriched alterations within the respective predicted PDX subtypes (Fig. 4C). In particular, the LUAD PPR subtype was reported to be enriched in *STK11* and *KRAS* alterations in other PT datasets, and the PDX models classified as PPR subtype showed higher frequencies of these alterations compared other subtypes. The same observation can also be made for the *NFE2L2* alteration enriched in LUSC CLA subtype. As such, the PDX models displayed subtype-specific expression and/or alteration profiles similar to those reported in patient tumor subtyping studies.




Figure 4. Gene expression in lung cancer PDX models. **A**, Hierarchical clustering of gene expression percentile rank z-score for all lung cancer PDX samples and platforms. The heatmap is based on correlation values of expression percentile rank z-score expression for LUSC and LUAD PDX samples from sequencing and array platforms. The top horizontal color bars indicate the library preparation methods and platforms, subtype designation, and passage number. Sample labels are indicated by model ID, sample ID, and library preparation/platform. **B**, Expression (quantile-normalized raw RSEM counts) correlation of nearest template prediction genes between TCGA (LUAD, $n = 230$; LUSC, $n = 178$) and PDX (LUAD, $n = 36$; LUSC, $n = 24$) samples for LUAD and LUSC. The color bars indicate the subtype labels for TCGA and subtype predictions for PDX. **C**, Proportion of PDX models with mutations reported to be enriched in LUAD and LUSC subtypes as indicated on the left. LUAD subtypes: proximal-inflammatory (PIF), proximal-proliferative (PPR), terminal respiratory unit (TRU). LUSC subtypes: basal (BAS), classical (CLA), primitive (PRI), and secretory (SEC).

Treatment responses in PDX models

Many of the tumors submitted for PDX generation were selected on the basis of the presence of clinically relevant mutations per National Comprehensive Cancer Network (NCCN) guidelines (Supplementary Table S1; refs. 10, 25, 54). Cohorts of tumor-bearing mice of a subset of the lung cancer PDX models were enrolled in dosing studies to evaluate responses to drug treatment. A summary of treatment responses is illustrated for LUAD models (Supplementary Fig. S7A), LUSC models (Supplementary Fig. S7B), and other lung models in the collection (Supplementary Fig. S7C).

Targeted treatment of EGFR-mutant PDXs

Nine PDX models in the JAX collection harbor activating mutations in *EGFR* (L858R, exon 19 deletion, exon 20 insertion) and were tested for response to TKI. Six of the models (TM00199, TM00204, TM00219, TM00253, and TM00784) were derived from patients at the time of progression on either single-agent or combinations of erlotinib; two of the models (J000100672 and TM00193) were derived from treatment-naïve patients. Both TM00204 and TM00219 harbor the *EGFR* T790M mutation, and TM00784 harbors *MET* amplification. These markers are associated with acquired resistance to treatment with TKIs (10, 54). J000100672 harbors the exon 20 insertion associated with *de novo* resistance to TKI inhibitors (55). TM00253 harbors the mutation *EGFR* V834L, which is associated with decreased response to erlotinib (56). Cohorts of tumor-bearing mice of these models, except for TM00193, were treated with single-agent erlotinib. TM00199 displayed partial response (PR), TM00253 displayed stable disease (SD), and the other four models with TKI treatment resistance mutations displayed progressive disease (PD; Fig. 5A; Supplementary Figs. S7A and S8). The lack of complete response (CR) recapitulated the treatment response observed in the patients and the response expected from the *EGFR* mutation status of these models.

Two models (TM00199 and TM00219) were tested using second-generation agents to evaluate treatment options following the development of resistance to first-generation TKIs (56). The models were treated with a combination of afatinib and cetuximab along with single-agent erlotinib, afatinib, cetuximab, and vehicle controls. As expected, TM00199 did not exhibit significant tumor growth inhibition upon treatment with erlotinib. Single-agent afatinib-treated animals subsequently progressed after a succession of treatment, whereas animals treated with cetuximab (with or without afatinib) exhibited CR. The treatment effects on *EGFR* expression and phosphorylation were examined at 6- and 24-hour time points (Fig. 6). After a single treatment, the *EGFR* TKIs erlotinib and afatinib resulted in notable downregulation of *EGFR* phosphorylation within six hours, rebounding to control levels after 24 hours (Fig. 6A; Supplementary Fig. S11). In contrast, cetuximab showed evidence of moderate downregulation by 6 and 24 hours accompanied by diminished total protein expression. The combination of afatinib plus cetuximab resulted in ablated phosphorylation at 6 hours in two of three models, maintained at the 24 hours time points, associated with reduced protein expression.

The TM00219 model was derived from a patient at the time of erlotinib progression, associated with the emergence of the T790M *EGFR* resistance mutation, which was observed in both the patient post-erlotinib treatment biopsy and the engrafted tumor. This model showed no benefit from erlotinib or cetuximab, with marginal activity from afatinib. In this unresponsive model, none of the *EGFR*-targeted agents could entirely suppress *EGFR* phosphorylation at 6 or 24 hours (Fig. 6B; Supplementary Fig. S11).

Targeted treatment of an EML4-ALK fusion PDX model

LUAD model TM00206 harbors the *EML4-ALK* fusion and, as expected, had a robust response to treatment with the *ALK* TKI, crizotinib (Fig. 5A; Supplementary Figs. S7A and S9; ref. 57). The response at the cohort level was categorized as a CR. However, 2 of the 9 mice in the treatment cohort were classified as PR. Acquired crizotinib resistance has been reported in *ALK*-rearranged NSCLCs (58) and the clinical records for the patient reveal that the individual's cancer progressed while on treatment. The variability in the response in the corresponding individual mice may be due to the presence of resistant subclones. Although the treated PDXs were not tested for known resistance variants, the genomic data from two early passage (P0) tumors for this model revealed the presence of reported resistance mutations at a subclonal level. The *ALK* L1196M mutation was detected at an allelic frequency of 22% and a low-level *KIT* amplification [$\log(\text{CN}/\text{ploidy}) = 0.43$] was detected in one of the P0 tumors (LG0812PE1330P0), whereas low-level amplification in *ALK* and *EML4*, possibly the fusion, was detected in another P0 sample (LG0812PE1332P0).

Treatment of KRAS-mutant PDXs

Twelve models in the collection harbor loss-of-function *KRAS* mutations that result in downstream pathway activation (Supplementary Table S1) and were treated with a *MEK1/2* inhibitor (trametinib). Trametinib acts through the inhibition of the MAPK pathway downstream of *KRAS*. Although most models exhibited no growth inhibition from trametinib and no cohort-level responses surpassed the threshold of PD, the per animal response data for five of the models (TM00226, J000095635, TM00186, TM00203, TM00233) had at least 2 animals in the cohort with a response classification of SD (Supplementary Fig. S7A), suggesting moderate activity of the drug in some animals. This result is consistent with clinical trials that demonstrated single-agent trametinib showed no improved efficacy compared with docetaxel in patients with advanced *KRAS*-mutant NSCLC (Fig. 5B; Supplementary Fig. S7A; ref. 59). PR was observed for the combination of docetaxel and trametinib for model J000095635 (*KRAS* G12D) compared with single-agents (SD and PD, respectively). For model J000096652 (*KRAS* G12C), the combination docetaxel and trametinib showed no additional benefit over single-agent docetaxel. Both treatment arms were classified as PR (Fig. 5A; Supplementary Figs. S7A and S10).

Discussion

The treatment of NSCLC has rapidly evolved, with chemotherapy being replaced by either targeted therapies or immunotherapy in many cases. For treatment advances to continue, preclinical models that accurately reflect the complexity and heterogeneity of human cancers, as well as being predictive of drug sensitivity and resistance patterns observed in patients, are mandatory. Given the complexities of drug-tumor interactions together with inter- and intra-patient tumor heterogeneity, PDX models stand apart in the preclinical arena as experimentally tractable and reproducible models that recapitulate the clinically relevant genomic properties and treatment responses of the patient tumors from which they are derived.

The repository of lung cancer PDX models described here was generated, characterized, and annotated in collaboration with clinical investigators. For models with corresponding patient tumor genomic data, the implanted tumors in the lung PDXs maintained the histologic characteristics and genomic properties of patient tumors from which they were derived. Treatment responses for targeted agents in the




Figure 5.

Summary of treatment responses in lung PDX models. LUAD (A), LUSC (B), and all other lung cancer types (C). Treatment responses were calculated as percent change in tumor volume for each animal as $V: [(end_volume - start_volume) / start_volume] \times 100$ at day 21. Within each group the minimum (V_m) and average volume (V_a) were calculated with response classifications calculated as follows: CR, $V_m < -95\%$, $V_a < -40\%$; PR, $V_m < -50\%$, $V_a < -20\%$; SD, $V_m < 35\%$, $V_a < 30\%$; PD, anything else. The number of treatments in each RECIST category is shown at the top, and number of models in each RECIST category is shown on the right side of each plot. The color bar at the bottom indicates the treatment naïve and mutation status (KRAS, EGFR, and EML4-ALK fusion) of each model. Plots were generated with the R package Xeva (version 1.6.0).

models were consistent with expectations based on the presence of specific molecular targets and also recapitulated the treatment responses of patients treated with the same agents. The PDX models available from the JAX repository are a validated resource for

preclinical investigations into the efficacy of new cancer treatments and for basic research into the mechanisms of acquired resistance to target-directed therapies and for developing strategies to overcome treatment resistance.




Figure 6.

Treatment-induced changes in phosphorylation of *EGFR*, *AKT*, *ERK*, and *p38* at 6 and 24 hours in lung PDX models treated with erlotinib, afatinib, cetuximab, and afatinib+cetuximab. Studies were conducted in triplicate for each time point, independently in different animals. *AKT*, *ERK1*, and *p38* phosphorylation state were examined to evaluate changes in downstream signal transduction, with the understanding that the timing of effects will be subject to variation across models. **A**, In model TM00199, a single treatment of erlotinib and afatinib induced downregulation of *EGFR* phosphorylation within six hours, rebounding to control levels after 24 hours. Treatment with cetuximab demonstrated moderate downregulation by six hours in two of three models and substantial downregulation at 24 hours in three of three models, accompanied by diminished total protein expression. The combination of afatinib plus cetuximab resulted in ablated phosphorylation at 6 hours in two of three models, maintained at the 24 time points, associated with reduced protein expression. **B**, In model TM00219, none of the *EGFR*-targeted agents could entirely suppress *EGFR* phosphorylation at 6 or 24 hours.

Authors' Disclosures

R. Gandour-Edwards reports other support from UC DAVIS during the conduct of the study. J.W. Riess reports personal fees from Blueprint, Beigene, Daiichi Sankyo, Novartis, Roche/Genentech, EMD Serano, Regeneron, Sanofi, Turning Point, BMS, Boehringer Ingelheim, and Janssen; grants from AstraZeneca, Boehringer Ingelheim, Novartis, Spectrum, Merck, and Revolution Medicines outside the submitted work. C. Paisie reports grants from Jackson Laboratory for Genomic Medicine during the conduct of the study. C.G. Tepper reports grants from NCI (P30 CA93373) during the conduct of the study. D.R. Gandara reports research grants: Amgen (institutional), AstraZeneca (institutional), Genentech (institutional), Merck (institutional); consultant/advisory boards: Adagene, Inc. (institutional), AstraZeneca (institutional), Roche-Genentech (institutional), Guardant Health (institutional), IO Biotech (institutional), Oncocyte (institutional), OncoHost (institutional), Lilly (consultant), Merck (consultant), Novartis (consultant). No disclosures were reported by the other authors.

Authors' Contributions

X.Y. Woo: Conceptualization, formal analysis, methodology, writing—original draft, writing—review and editing. A. Srivastava: Conceptualization, formal analysis, supervision, methodology, writing—original draft, writing—review and editing. P.C. Mack: Conceptualization, formal analysis, investigation, methodology, writing—original draft, writing—review and editing. J.H. Graber: Conceptualization, software, formal analysis, validation, visualization, methodology, writing—original draft, writing—review and editing. B.J. Sanderson: Software, formal analysis. M.W. Lloyd: Software, formal analysis. M. Chen: Formal analysis. S. Domanskyi: Formal analysis. R. Gandour-Edwards: Data curation, formal analysis, methodology, writing—review and editing. R.A. Tsai: Investigation. J. Keck: Conceptualization, resources, supervision. M. Cheng: Supervision, methodology. M. Bundy: Resources, data curation, methodology. E.L. Jocoy: Conceptualization, resources, supervision, methodology, project administration. J.W. Riess: Methodology, writing—review and editing. W. Holland: Investigation. S.C. Grubb: Software,

formal analysis, methodology. **J.G. Peterson:** Software, formal analysis, methodology. **G.A. Stafford:** Data curation, formal analysis, methodology. **C. Paisie:** Formal analysis. **S.B. Neuhauser:** Software, formal analysis, methodology. **R.K.M. Karuturi:** Supervision, writing–review and editing. **J. George:** Methodology, writing–review and editing. **A.K. Simons:** Software, formal analysis, visualization, methodology. **M. Chavaree:** Data curation. **C.G. Tepper:** Formal analysis, writing–review and editing. **N. Goodwin:** Conceptualization, methodology, writing–review and editing. **S.D. Airhart:** Conceptualization, methodology, project administration. **P.N. Lara Jr:** Resources, funding acquisition. **T.H. Openshaw:** Resources, investigation, methodology. **E.T. Liu:** Conceptualization, resources, funding acquisition, writing–review and editing. **D.R. Gandara:** Conceptualization, resources, funding acquisition, investigation, methodology, writing–original draft, writing–review and editing. **C.J. Bult:** Conceptualization, resources, data curation, software, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing–original draft, project administration, writing–review and editing.

Acknowledgments

P30 CA034196 (to E.T. Liu), P30 CA093373 (to P.N. Lara), SU2C 201502309 (to D.R. Gandara), 5U01 CA180944 (to E.T. Liu), R01 CA089713 (to C.J. Bult). The Jackson Laboratory Director’s Innovation Fund (to C.J. Bult and S.D. Airhart), the Maine Cancer Foundation (to C.J. Bult), the Kleeberg Foundation (to C.J. Bult), and the Hope Foundation (to E.T. Liu). The authors express their deep appreciation to the patients who generously consented to have their tumor tissues used to generate the patient-derived cancer models described in this manuscript and to make these models broadly available for basic and pre-clinical cancer research. The generation and characterization of models in

the JAX lung cancer PDX repository was funded by The Jackson Laboratory Director’s Innovation Fund, the Maine Cancer Foundation, the Kleeberg Foundation, the Hope Foundation, and the Integrated Translational Science Center (ITSC) (5U01 CA180944). Genome data analysis was supported, in part, by the JAX Cancer Center Computational Sciences Shared Service (P30 CA034196). The PDX Web portal was developed with support from R01 CA089713. Additional support provided by the UCD Comprehensive Cancer Center (P30CA093373), the UCAMP Minority PDX Center (U54CA233306), the Susan and Jerry Knapp and the Addario Foundation, and Stand Up to Cancer (SU2C 201502309). The UCD Pathology Biorepository assisted with collection and histological interpretation of specimens. RNA-seq data for patient and PDX tumors used as part of the expression-based subtype analysis were obtained from the NCI Patient-Derived Models Repository (PDMR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Note

Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Received March 20, 2022; revised June 22, 2022; accepted September 1, 2022; published first September 7, 2022.

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49.
- Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. *Nature* 2020;578:94–101.
- Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 2013;499:214–8.
- Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. *J Clin Oncol* 2006;24:5079–90.
- Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. *Clin Cancer Res* 2010;16:4864–75.
- Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res* 2014;4:36–54.
- Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmieielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543–50.
- Lee CS, Milone M, Seetharamu N. Osimertinib in EGFR-mutated lung cancer: a review of the existing and emerging clinical data. *Onco Targets Ther* 2021;14:4579–97.
- Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693–703.
- Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong K-K, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci U S A* 2008;105:2070–5.
- Woo XY, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. *Nat Genet* 2021;53:86–99.
- Simpson KL, Stoney R, Frese KK, Simms N, Rowe W, Pearce SP, et al. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. *Nat Cancer* 2020;1:437–51.
- Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C, et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. *Cancer Med* 2015;4:201–11.
- Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. *Cancer Discov* 2018;8:600–15.
- Zhang X-C, Zhang J, Li M, Huang X-S, Yang X-N, Zhong W-Z, et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. *J Transl Med* 2013;11:168.
- Stewart EL, Mascaux C, Pham N-A, Sakashita S, Sykes J, Kim L, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. *J Clin Oncol* 2015;33:2472–80.
- Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, et al. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. *Cancer* 2019;125:3738–48.
- Lee P-C, Fang Y-F, Yamaguchi H, Wang W-J, Chen T-C, Hong X, et al. Targeting PKC δ as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer. *Cancer Cell* 2018;34:954–69.
- Woo XY, Srivastava A, Graber JH, Yadav V, Sarsani VK, Simons A, et al. Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. *BMC Med Genet* 2019;12:92.
- Krupke DM, Begley DA, Sundberg JP, Richardson JE, Neuhauser SB, Bult CJ. The mouse tumor biology database: a comprehensive resource for mouse models of human cancer. *Cancer Res* 2017;77:e67–70.
- Conte N, Mason JC, Halmagyi C, Neuhauser S, Mosaku A, Yordanova G, et al. PDX Finder: a portal for patient-derived tumor xenograft model discovery. *Nucleic Acids Res* 2018;47:D1073–D9.
- Tsongalis GJ, Wu AH, Silver H, Ricci A Jr. Applications of forensic identity testing in the clinical laboratory. *Am J Clin Pathol* 1999;112:93–103.
- Chen K, Ahmed S, Adeyi O, Dick JE, Ghanekar A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with epstein-barr virus. *PLoS One* 2012;7:e39294.
- Ananda G, Mockus S, Lundquist M, Spotlow V, Simons A, Mitchell T, et al. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. *Exp Mol Pathol* 2015;98:106–12.

25. Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. *Hum Genomics* 2016;10:4.
26. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. *Bioinformatics* 2013;30:1015–6.
27. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. *Genome Res* 2018;28:1747–56.
28. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012;2:401–4.
29. Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. *JCO Precis Oncol* 2017:1–16.
30. Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, et al. GenVisR: genomic visualizations in R. *Bioinformatics* 2016;32:3012–4.
31. Eide PW, Bruun J, Lothe RA, Sveen A. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. *Sci Rep* 2017;7:16618.
32. Hammerman PS, Lawrence MS, Voet D, Jing R, Cibulskis K, Sivachenko A, et al. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519–25.
33. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res* 2015;44:e71.
34. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
35. Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 2019;569:503–8.
36. Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat Med* 2015;21:1318–25.
37. Mer AS, Ba-Alawi W, Smirnov P, Wang YX, Brew B, Ortmann J, et al. Integrative pharmacogenomics analysis of patient-derived xenografts. *Cancer Res* 2019;79:4539–50.
38. Holland WS, Chinn DC, Lara PN Jr, Gandara DR, Mack PC. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. *J Cancer Res Clin Oncol* 2015;141:615–26.
39. Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskiy O, Gursel D, et al. Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. *Neoplasia* 2015;17:735–41.
40. John T, Yanagawa N, Kohler D, Craddock KJ, Bandarchi-Chamkhaleh B, Pintilie M, et al. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. *J Thorac Oncol* 2012;7:1101–8.
41. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. Xenome—a tool for classifying reads from xenograft samples. *Bioinformatics* 2012;28:i172–i8.
42. Wang VG, Kim H, Chuang JH. Whole-exome sequencing capture kit biases yield false negative mutation calls in TCGA cohorts. *PLoS One* 2018;13:e0204912.
43. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. *N Engl J Med* 2017;376:2109–21.
44. Gandara DR, Hammerman PS, Sos ML, Lara PN, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. *Clin Cancer Res* 2015;21:2236–43.
45. Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen H-Z, et al. Landscape of microsatellite instability across 39 cancer types. *JCO Precis Oncol* 2017:1–15.
46. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther* 2017;16:2598–608.
47. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* 2020;21:1353–65.
48. André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-Instability-high advanced colorectal cancer. *N Engl J Med* 2020;383:2207–18.
49. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med* 2017;9:34.
50. Qiu Z-W, Bi J-H, Gazdar AF, Song K. Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer. *Genes Chromosomes Cancer* 2017;56:559–69.
51. Shao X, Lv N, Liao J, Long J, Xue R, Ai N, et al. Copy number variation is highly correlated with differential gene expression: a pan-cancer study. *BMC Med Genet* 2019;20:175.
52. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. *PLoS One* 2012;7:e36530.
53. Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, et al. Nongenetic evolution drives lung adenocarcinoma spatial heterogeneity and progression. *Cancer Discov* 2021;11:1490–507.
54. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. *MET* amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316:1039–43.
55. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. *Lancet Oncol* 2012;13:e23–31.
56. Sarcar B, Gimbrone NT, Wright G, Remsing Rix LL, Gordian ER, Rix U, et al. Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. *FEBS Open Bio* 2019;9:1689–704.
57. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385–94.
58. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. *Sci Transl Med* 2012;4:120ra17.
59. Blumenschein GR, Smit EF, Planchard D, Kim DW, Cadranet J, De Pas T, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. *Ann Oncol* 2015;26:894–901.